<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6371">
  <stage>Registered</stage>
  <submitdate>9/03/2017</submitdate>
  <approvaldate>9/03/2017</approvaldate>
  <nctid>NCT03086135</nctid>
  <trial_identification>
    <studytitle>Clinical Performance of a New Implant System for Bone Conduction Hearing</studytitle>
    <scientifictitle>Clinical Performance of a New Implant System for Bone Conduction Hearing</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBAS5539</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Deafness; Sensoneural Single Sided</healthcondition>
    <healthcondition>Conductive Hearing Loss</healthcondition>
    <healthcondition>Mixed Hearing Loss</healthcondition>
    <conditioncode>
      <conditioncode1>Ear</conditioncode1>
      <conditioncode2>Deafness</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Osia System

Experimental: Bone-conduction hearing device - The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.


Treatment: devices: Osia System
An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hearing performance: threshold audiometry PTA4, unaided versus OSIA system at 3 months - The change of hearing performance with the OSIA system (aided) at 3 months from the unaided hearing performance before surgery; measured as free-field hearing tests: Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz).</outcome>
      <timepoint>Baseline before surgery, 3 months after surgery</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Speech in quiet at 65dB, unaided versus OSIA system at 3 months - The change of hearing performance [% correctly perceived words at 65dB SPL] with the OSIA System at 3 months compared to the pre-operative unaided situation; Speech in quiet at 65 dB SPL</outcome>
      <timepoint>Baseline before surgery, 3 months after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hearing performance: threshold audiometry PTA4, unaided versus OSIA system at 12 months - The change of hearing performance with the OSIA system (aided) at 12 months from the unaided hearing performance before surgery; measured as free-field hearing tests: Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz).</outcome>
      <timepoint>Baseline before surgery, 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hearing performance: threshold audiometry individual frequences, unaided versus OSIA system - The change of hearing performance with the OSIA system (aided) from the unaided hearing performance before surgery; measured as free-field hearing tests: Threshold audiometry (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz).</outcome>
      <timepoint>Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Speech in quiet at 50, 65 and 80 dB SPL, unaided versus OSIA system - The change of hearing performance [% correctly perceived words at 50, 65 and 80 dB SPL] with the OSIA System compared to the pre-operative unaided situation; Speech in quiet at 50, 65 and 80 dB SPL</outcome>
      <timepoint>Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adaptive Speech Recognition in Noise, unaided versus OSIA system - The change of hearing performance with the OSIA System compared to the pre-operative unaided situation; Adaptive speech recognition in noise measured as signal to noise ratio</outcome>
      <timepoint>Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Abbreviated Profile of Hearing Aid Benefit (APHAB) - Measuring change of Ease of communication, Reverberation, Background noise, Aversiveness and a Global score with the OSIA System from the pre-operative unaided situation. The absolute APHAB scale is between 0 and 100%, where 0% indicates no problems and 100% indicates always problem. The change from unaided to aided hearing is presented. A positive value indicates an improvement, a negative value an impairment.</outcome>
      <timepoint>Baseline before surgery, 3 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Utility Index (HUI) - Change of health status and health related quality of life using the generic quality of life scale Health Utilities Index (HUI3) when wearing OSIA System compared to the pre-operative unaided situation. A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death. The change from unaided to aided hearing is presented. A positive value indicates an improved quality of life, a negative value indicates impaired quality of life.</outcome>
      <timepoint>Baseline before surgery, 3 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Speech, Spatial and Qualities of Hearing Scale (SSQ) - Measuring change of speech, spatial and hearing experiences with the OSIA System from the pe-operative unaided situation. A scale from 0 to 10 is used, where 0 represents "can not hear at all", and 10 "hear perfectly". The change from unaided to aided hearing is presented. A positive value indicates improved hearing, a negative value indicates impaired hearing.</outcome>
      <timepoint>Baseline before surgery, 3 and 12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hearing performance: threshold audiometry PTA4, with reference device BP110 - Hearing performance with the reference device BP110 on a softband (aided) before surgery; measured as free-field hearing tests: Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz).</outcome>
      <timepoint>Baseline before surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hearing performance: threshold audiometry individual frequences with reference device BP110 - Hearing performance with the reference device BP110 on a softband (aided); measured as free-field hearing tests: Threshold audiometry (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz).</outcome>
      <timepoint>Baseline before surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Speech in quiet at 50, 65 and 80 dB SPL, with reference device BP110 - Hearing performance [% correctly perceived words at 65dB SPL] with the reference device BP110 on a softband (aided); Speech in quiet at 50, 65 and 80 dB SPL</outcome>
      <timepoint>Baseline before surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adaptive Speech Recognition in Noise, with reference device BP110 - Hearing performance with the reference device BP110 on a softband (aided); Adaptive speech recognition in noise measured as signal to noise ratio</outcome>
      <timepoint>Baseline before surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: time of surgery - Surgery time in minutes between first incision and last suture</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: soft tissue thickness - Soft tissue thickness in mm</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: soft tissue reduction - Yes or no</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: bone polishing/temoval at Implant site - Yes or no</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: type of anaesthesia - Type of anaesthesia: local or general</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: Location of BI300 implant - Measured in mm from ear channel</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical information: Incision type - Anterior based or posterior based flap</outcome>
      <timepoint>Visit 2, surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily use of Sound Processor: usage time - Usage time measured as hours per day</outcome>
      <timepoint>6 weeks, 3, 6 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily use of Sound Processor: comfort - Measured with a visual analogue scale</outcome>
      <timepoint>6 weeks, 3, 6 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnet choice - Magnet strength: 1/2, 1, 2, 3, 4, 5 or 6</outcome>
      <timepoint>4, 6 weeks, 3, 6 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Softpad use - Yes or no</outcome>
      <timepoint>6 weeks, 3, 6 and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult subjects (18 years or older)

          -  Subject with conductive or mixed hearing loss in the ear to be implanted. Bone
             conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 4 kHz) of 55
             dB HL.

        OR Subject with single-sided sensorineural deafness who is a candidate for Baha surgery.
        Air conduction thresholds with a pure tone average PTA4 of 20 dB HL (mean of 0.5, 1, 2 and
        3 kHz) in the good ear OR subject who is indicated for an AC CROS butfor some
        reasoncannot or will not use an AC CROS (Air Conduction-Contralateral Routing of Signal).

          -  Signed informed consent

          -  Previous experience from amplified sound though a non-surgical solution. (For example
             but not limited to Hearing aid, CROS device, Bone conductional hearing device on
             headband/ softband)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Uncontrolled diabetes as judged by the investigator.

          -  Condition that could jeopardise osseointegration and/or wound healing (e.g.
             osteoporosis, psoriasis, long-term systemic use of corticosteroids) or condition that
             may have an impact on the outcome of the investigation as judged by the investigator.

          -  Insufficient bone quality and quantity for implantation of a BI300 Implant.

          -  Subject that has received radiotherapy in the area of implantation, or is planned for
             such radiotherapy during the study period

          -  Use of ototoxic drugs that could be harmful to the hearing, as judged by the
             investigator

          -  Unable to follow investigational procedures, e.g. to complete quality of life scales.

          -  Participation in another clinical investigation with pharmaceutical and/or device.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>9/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Victorian Eye and Ear Hospital - East Melbourne</hospital>
    <postcode>VIC 3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-WÃ¼rttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Nadarzyn</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cochlear Bone Anchored Solutions</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To study the initial experience with implanting and fitting the new Bone conduction system in
      patients with conductive, mixed or Single sided Sensorineural deafness.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03086135</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Emmanuel Mylanus, Prof.</name>
      <address>Radboud Univerity Medical centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Johan Blechert, M.Sc</name>
      <address />
      <phone>0046317924632</phone>
      <fax />
      <email>Jblechert@cochlear.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>